Groundbreaking Study: Diabetes & Obesity Drugs Offer Kidney Protection

New Study: Diabetes and Obesity Drugs May Protect Kidneys

A recent study suggests that popular diabetes and obesity medications could help protect the kidneys. These drugs might reduce the risk of kidney issues, even in people without diabetes.

The research reveals a 19% overall reduction in the risk of kidney failure, worsening kidney function, and death due to kidney disease. Known as GLP-1 receptor agonists, these medications mimic a hormone that stimulates insulin production and lowers blood sugar levels. They were initially developed to treat diabetes but have also proven effective for weight loss by slowing digestion and reducing hunger.

Lead author Professor Sunil Badve from The George Institute for Global Health stated that this study highlights the benefits of GLP-1 receptor agonists for both diabetic and non-diabetic patients, particularly those with chronic kidney disease (CKD). CKD can lead to severe complications, such as kidney failure and premature death.

The research analyzed 11 large clinical trials involving 85,373 participants. It included several GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza). Compared to placebo, these medications reduced the risk of kidney failure by 16% and worsened kidney function by 22%.

The study also confirmed that GLP-1 receptor agonists benefit heart health, showing a 14% reduction in the risk of cardiovascular death, heart attack, and stroke.

Senior author Professor Vlado Perkovic emphasized the significance of this research. He stated that these findings could reshape clinical guidelines for managing CKD and cardiovascular diseases. More efforts are needed to implement these results in clinical practice and ensure that those who need these medications can access them.